Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Dermatol Online J ; 23(2)2017 Feb 15.
Article in English | MEDLINE | ID: mdl-28329500

ABSTRACT

El acantoma de la vaina pilosa es un tumor benignode piel muy poco frecuente. Suele presentarse comouna pápula asintomática, con un orificio central y lalocalización más frecuente es la cara. Presentamos unnuevo caso de acantoma de vaina pilosa, apoartandoimagen dermatoscópica del tumor.


Subject(s)
Acanthoma/diagnosis , Facial Neoplasms/diagnosis , Skin Neoplasms/diagnosis , Acanthoma/pathology , Adult , Facial Neoplasms/pathology , Humans , Male , Skin Neoplasms/pathology
3.
Eur J Dermatol ; 25(5): 410-7, 2015.
Article in English | MEDLINE | ID: mdl-26080687

ABSTRACT

BACKGROUND: Information on the long-term efficacy of etanercept (ETN) treatment of moderate-to-severe psoriasis according to the Summary of Product Characteristics (SmPC) is scarce. OBJECTIVES: We report the efficacy results of an observational clinical trial including 202 patients treated for 12 months with ETN according to SmPC. METHODS: Concomitant topical treatment was permitted throughout the study period. Efficacy assessment was done by intention-to-treat analysis with last observation carried forward. RESULTS: Mean % Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) decreased from 39.0% and 22.2% at baseline to 7.9% and 4.4%, respectively, at 12 months. Throughout the study duration, PASI 50, PASI 75 and PASI 90 response rates ranged from 72.8% to 95.7%, 55.6% to 84.3%, and 36.1% to 62.2%, respectively. Body mass index and body weight had minor effects on treatment efficacy. CONCLUSION: ETN treatment according to the SmPC provided sustained improvement of psoriasis throughout one year.


Subject(s)
Etanercept/therapeutic use , Immunosuppressive Agents/therapeutic use , Psoriasis/diagnosis , Psoriasis/drug therapy , Adult , Analysis of Variance , Cohort Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Middle Aged , Risk Assessment , Severity of Illness Index , Spain , Statistics, Nonparametric , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL